Audit: QRS - Resistant Starch for Health & Longevity
Audit conducted on 11/05/2026 14:36 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 97 |
| Passed | 88 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Lede, Protocol, Time to effect, Benefits, Risks, gates and Monitoring all trace to ER text (Conclusion, Therapeutic Protocol, Practical Considerations, Expected Benefits, Risks, Key Interactions, Monitoring table) |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedges kept where no tier carries them: “Small reduction likely” (time_3), “may fall” (markers 2, 5), “At most a slight fall” (marker 3) |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; lede “small, inconsistent” mirrors ER Conclusion |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications from “Populations who should avoid”; interactions from Theoretical group; benefits and risks in ER tiers |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, expert or brand names in the QRS |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches ER’s measured, evidence-weighted tone |
| 2.2 | The tone of the QRS is expert, accessible, objective, and data-driven | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Protocol and cadence stated as ER facts, not advice |
| 2.6 | The QRS never addresses the reader directly — it presents evidence, not guidance | 🟢 | No second-person address |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms (RS2, HbA1c, HOMA-IR, SIBO, TMAO, GLP-1, ALT) are ER labels carried verbatim |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.10 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.11 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Lede notes gains clearest with insulin resistance or excess weight |
| 2.13 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording |
| 2.14 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No colloquial route or event terms; “gas”, “food poisoning” are the ER’s own terms |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels and column headers unchanged |
| 3.2 | Every element carrying a data-qrs-var attribute in [qrs_template] is present in the QRS with the same name | 🟢 | All template data-qrs-var names present; marker_# expanded to 1-7, qualitative_item_# to 1-4 |
| 3.3 | Everything outside the data-qrs-var spans — markup, text, styles, comments — is as in the template; spans that no checklist item addresses are left unchanged as well | 🟢 | Diff against template shows changes only inside data-qrs-var spans, metadata values and the risks_high display:none required by 13.5 |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | An empty ER section never produces visible empty-state text in the QRS: the corresponding region is hidden or left empty. Phrases such as “None documented in human trials to date” or “Not formally studied” appear only where the ER uses them for a fact the QRS carries over. | 🟢 | No visible empty-state text; empty High risk tier hidden |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels, interaction labels and qualitative bold labels use ER bold labels |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels verbatim; only glosses and surplus examples trimmed |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in QRS |
| 4.5 | The QRS is designed to render on one A4 page. It fails this item only for one of four things: a trailing clause after a dash, an optional gloss, an example list left untrimmed, or a repetition. Nothing else is cut to fit. | 🟢 | No trailing dash clause, optional gloss, untrimmed example list or repetition found |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration quoted (contains a colon) |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | 26.10.25 matches QRS.md |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | 2026-1105-1405 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT); when the full name has no version number or is “Unknown”, the nickname equals the full name | 🟢 | Opus |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y), the model name alone when the system prompt or developer instructions name a model without a version number (e.g., Grok), or “Unknown” when neither the system prompt nor the developer instructions of the creating model name a model | 🟢 | Opus 5.5 |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Resistant Starch for Health & Longevity - Quick Reference Sheet |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 11/05/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Opus 5.5 |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “Resistant starch, a dietary starch … used to improve blood sugar control” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER Conclusion, incl. “Replacing ordinary starch” action cue |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | Exactly 70 words |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each fact maps to ER Motivation or Conclusion |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; plain terms |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Three items from “Populations who should avoid Resistant Starch” |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Plant list and Crohn’s example kept |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation in ER items |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the ER’s documented interactions — the items under its “Documented interactions:” label — excluding any that are already listed as Contraindications and any entry phrased as no interaction found | 🟢 | All three documented entries are null (“no interaction found” / “no harmful interaction reported”); span empty with basis comment |
| 9.3 | [caution_theoretical_items] represent the ER’s theoretical interactions — the items under its “Theoretical interactions (inferred from mechanism, not studied in humans):” label | 🟢 | All 7 theoretical items present |
| 9.4 | The ER placeholder “None identified” is never an item: it means that group is empty | 🟢 | |
| 9.5 | Individual [caution_items] and [caution_theoretical_items] are formatted as <li></li>. The template’s bold “Theoretical (inferred from mechanism)” sub-heading is the only marker of the second list’s status: no item carries “(theoretical)”, “inferred from” or a mechanism clause | 🟢 | No item carries “(theoretical)” or “inferred from” |
| 9.6 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 9.7 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists kept; “mainly relevant with glucose-lowering drugs” qualifier kept |
| 9.8 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation in ER items |
| 9.9 | If the ER’s theoretical group is empty, the whole Theoretical block — the caution_theoretical span with its sub-heading and list — is hidden with style="display:none", not removed: its spans stay in place, empty. |
N/A | Theoretical group not empty |
| 9.10 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated via Theoretical list |
| 9.11 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on, and the Theoretical block is hidden per 9.9. E.g. | N/A | Section not left empty |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Therapeutic Protocol section |
🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from that section | 🟢 | Supplemental RS2 dose, food-first, starch-substitution |
| 10.3 | If fewer than three distinct actionable implementation aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. |
N/A | ER has three or more aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from that section. | 🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Post-meal glucose, fasting glucose/insulin, LDL |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | High-tier benefit first, then Medium-tier benefits |
| 11.3 | If fewer than three distinct time-to-effect aspects are mentioned in the ER, the unused sets are left empty and hidden with style="display:none", not filled with placeholder text or empty-state phrasing. |
N/A | ER gives three or more aspects |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER provides no information on time to effect at all, the whole Time to effect block (its subhead and all three sets) is hidden with style="display:none", not removed: its spans stay in place, empty. |
N/A | ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items reduced to ER benefit headings, qualifiers (“Modest”) stripped |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content |
| 12.5 | If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A | All benefit tiers have items |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If a tier (high, medium, low, speculative) has no items, its span is hidden with style="display:none", not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | risks_high hidden with style=”display:none” |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring Protocol & Defining Success section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from that section are listed, one table row per marker; the template’s # row is the pattern, repeated with # replaced by 1, 2, 3 … in the data-qrs-var names |
🟢 | All 7 ER table biomarkers listed, rows 1-7 |
| 14.3 | [marker_#name] is the marker, [marker#target] its target value or range as given in the ER, [marker#_why] its purpose in a few words; a target the ER does not give is written “Not specified in the ER” | 🟢 | Targets match ER ranges |
| 14.4 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from that section. It is not left with placeholder text or empty. | 🟢 | Cadence from ER Monitoring paragraph |
| 14.5 | If the ER names no measurable biomarker, the table is hidden with style="display:none" and the single # row is left as in the template |
N/A | ER names measurable biomarkers |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring Protocol & Defining Success section |
🟢 | |
| 15.2 | All subjective/qualitative markers from that section are listed, one <li> per marker; the template’s # item is the pattern, repeated with # replaced by 1, 2, 3 … |
🟢 | All 4 ER qualitative markers listed |
| 15.3 | If the ER names no qualitative marker, the card’s list is hidden with style="display:none" and the single # item is left as in the template |
N/A | ER names qualitative markers |
Issues 11/05/2026 14:36
Pass rate 100.00%. No issues found.
Issues 11/05/2026 14:32
- 4.3 — Label shortened with ampersand: time_2_label at line 500 reads “Fasting glucose & insulin”, replacing the ER’s own word “and” (“fasting glucose and insulin effects”, ER Practical Considerations, Time to effect) with “&”.
Fixes 11/05/2026 14:32
- 4.3 — Label shortened with ampersand: Changed time_2_label from “Fasting glucose & insulin” to “Fasting glucose and insulin”, using the ER’s own wording.
Issues 11/05/2026 14:29
- 14.3 — HOMA-IR target incomplete: marker_2_target at line 616 reads “HOMA-IR: no established target” and drops the ER target “track change from own baseline” from the Fasting insulin / HOMA-IR row.
Fixes 11/05/2026 14:29
- 14.3 — HOMA-IR target completed: Changed marker_2_target from “HOMA-IR: no established target” to “HOMA-IR: no established target, track change from own baseline”, matching the ER Monitoring table.
Issues 11/05/2026 14:26
- 2.7 — Undefined abbreviation “RS”: action_3_value (line 475, “RS at least 14% of total starch”) and time_1_sub (line 495, “When RS replaces digestible starch”) use “RS”, which the sheet never defines and which is not part of an ER bold label carried verbatim.
Fixes 11/05/2026 14:26
- 2.7 — Spelled out abbreviation RS: Changed action_3_value from “RS at least 14% of total starch” to “Resistant starch at least 14% of total starch” and time_1_sub from “When RS replaces digestible starch” to “When resistant starch replaces digestible starch”.
Issues 11/05/2026 14:23
- 4.5 — Repeated LDL time-to-effect fact: marker_4_why at line 641 (“Small fall with intake beyond 4 weeks”) repeats the Time to effect set at lines 511-517 (“LDL cholesterol / Beyond 4 weeks / Small reduction likely with continued intake”).
Fixes 11/05/2026 14:23
- 4.5 — Repeated LDL time-to-effect fact: Changed marker_4_why from “Small fall with intake beyond 4 weeks” to “Small fall expected”, leaving the 4-week timing only in the Time to effect set.
Issues 11/05/2026 14:20
- 1.3 — Gate qualifier dropped: The theoretical “Glucose-lowering supplements (e.g., berberine, cinnamon extract): additive post-meal glucose lowering” item at line 561 omits the ER’s qualifier “mainly relevant for people also taking glucose-lowering drugs”, broadening an interaction the ER confines to that subgroup.
Fixes 11/05/2026 14:20
- 1.3 — Gate qualifier dropped: Appended “, mainly relevant with glucose-lowering drugs” to the theoretical glucose-lowering supplements item, restoring the ER’s applicability qualifier.
Issues 11/05/2026 14:15
- 1.2 / 1.3 — LDL hedge dropped: Time to effect cell time_3_sub at line 517 reads “Small reduction with continued intake”, omitting the ER’s “likely” (“a small LDL reduction is likely with intake beyond 4 weeks”), which strengthens a conflicted ER claim.
Fixes 11/05/2026 14:15
- 1.2 / 1.3 — LDL hedge dropped: Changed time_3_sub from “Small reduction with continued intake” to “Small reduction likely with continued intake”, restoring the ER’s hedge.
Issues 11/05/2026 14:12
- 2.12 — Audience signal difference missing: The At-A-Glance text (line 439) and the rest of the sheet omit the ER Conclusion’s point (ER line 425) that the gains are clearest in people who already have insulin resistance or excess weight, so the sheet does not show where the signal for a metabolically healthy reader differs.
Fixes 11/05/2026 14:12
- 2.12 — Audience signal difference added: Rewrote the At-A-Glance text (line 439) within 70 words to add the ER Conclusion’s point that the fasting blood sugar and cholesterol gains are “clearest with insulin resistance or excess weight”, shortening the post-meal sentence to fit.
Issues 11/05/2026 14:07
- 7.2 — Food-safety drawback omitted: Line 439 closes with “Gas and bloating are the main drawbacks.” although the ER Conclusion (line 427) names a second main drawback, the food-safety hazard of cooked rice or pasta left warm, which matters because the lede lists cooled cooked rice as a source.
Fixes 11/05/2026 14:07
- 7.2 — Food-safety drawback omitted: Changed the last At-A-Glance sentence from “Gas and bloating are the main drawbacks.” to “Main drawbacks: gas, bloating and food poisoning from cooked starch left warm.”, and shortened “reaches the large bowel undigested and is used to feed gut bacteria and improve” to “escapes digestion, feeds gut bacteria and is used to improve” so the lede stays at 70 words.